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Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme, statins,
are powerful cholesterol-lowering medications and have provided outstanding contri-
butions to the primary and secondary prevention of coronary heart disease. Low-
density lipoprotein cholesterol (LDL-C) is one of the major modifiable cardiovascular
risk factors, indeed, every 1.0mmol/L (38.7mg/dL) reduction in LDL cholesterolae-
mia corresponds to a 21% lowering in the risk of major vascular events. In this con-
text, the pharmacological approach with PCSK9 monoclonal antibodies is considered
a promising non-statin therapeutic option for the management of lipid disorders in
patients with persistent cardiovascular risk, including patients with diabetes melli-
tus. Data from two large clinical trials have indisputably demonstrated the efficacy
of alirocumab and evolocumab in preventive major adverse cardiovascular events in
high risk, secondary-prevention patients with clinical manifestation of atheroscle-
rotic cardiovascular diseases. Finally, PCSK9 monoclonal antibodies did not increase
the risk of serious adverse events, neurocognitive events, new-onset of diabetes,
muscle-related events, or myalgia.
Introduction
Low-density lipoproteins (LDLs) represent the most signifi-
cant biochemical variable associated with atheroma.
Indeed, in the process of atherogenesis, changes in endo-
thelial permeability and the composition of the extracellu-
lar matrix are associated to the entry and retention of
cholesterol-containing LDL particles in the artery wall.1
The importance of LDL lowering has been clearly demon-
strated by numerous meta-analyses showing that lowering
low-density lipoprotein cholesterol (LDL-C) by statins
reduces the risk of cardiovascular diseases (CVDs).
Moreover, prolonged exposure to lower LDL-C beginning
early in life, i.e. in the case of polymorphisms associated
with lower LDL-C levels, is associated with a greater reduc-
tion in the risk of CVD.2 Based on this evidence, it is worth
to understand how low we can go with LDL safely. Already
in 2014, data from statin trials demonstrated that patients
achieving very low LDL-C levels had a lower risk to develop
major cardiovascular (CV) events vs. those achieving mod-
erately low levels.3
Next step in this field was the IMPROVE-IT trial in which
ezetimibe added on top of statin led to an incremental fall
in LDL-C with a further benefit in the terms of clinical out-
comes.4 Prominent in this areawas the approval of two fully
human monoclonal antibodies against proprotein conver-
tase subtilisin/kexin type 9 (PCSK9), i.e. alirocumab (IgG1)
and evolocumab (IgG2), that have been approved in the
USA and in the European Union in August 2015.
Heterozygous (HeFH) and homozygous (HoFH) familial
hypercholesterolaemic patients can be treated with evolo-
cumab, whereas alirocumab may be prescribed only to
HeFH patients. Bococizumab, the third mAbs which under-
went a large Phase 3 trial programme, was discontinued
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due to the antidrug antibodies formation leading to an
over-time attenuation in the improvement vs. placebo of
lipid parameters. Bococizumabwas a humanized antibody.5
In particular, trials with PCSK9 monoclonal antibodies,
e.g. the FOURIER (Further Cardiovascular Outcomes
Research With PCSK9 Inhibition in Subjects With Elevated
Risk) study, reconfirmed a strong linear relationship be-
tween achieved LDL-C and CVevents, an effect going down
to LDL cholesterolaemia <8mg/dL.6 As of now, the best
characterized activity of secreted PCSK9 is to post-
translationally regulate the number of cell-surface LDL
receptors (LDLRs). PCSK9 binds to the LDLR, not allowing
the uptake of LDL particles from extracellular milieu into
cells; by this mechanism, PCSK9 raises LDL-C levels.7
Besides this evidence, some other pleiotropic effects have
been described: PCSK9 is expressed in endothelial cells,
vascular smooth muscle cells and, at low level, in macro-
phages. Vascular smooth muscle cells produce more PCSK9
than endothelial cells do, especially in response to shear
stress.8 PCSK9/mice are partially protected from neoin-
timal formation, further supporting the positive effect of
PCSK9 on intimal thickening.9 In humans, serum PCSK9 lev-
els are linearly associated with a higher necrotic core frac-
tion in coronary atherosclerosis10 and significantly
associated with arterial stiffness.11 Recently, we have
added circulating platelets to the list of targets of PCSK9,12
together with a direct pro-inflammatory effect on macro-
phages,13 and a positive effect on arterial and valvular
calcification.14
Since PCSK9 inhibitors reduced major adverse cardiac
events (MACEs) {RR 0.83 [95% confidence interval (CI):
0.78–0.88]}, but did not clearly reduce mortality [RR 0.93
(95% CI: 0.85–1.02)],15 the aim of this review article is to
briefly summarize the CV preventive activity of PCSK9 inhi-
bition which was evaluated in the ODYSSEY OUTCOMES
(Evaluation of Cardiovascular Outcomes After an Acute
Coronary Syndrome During Treatment With Alirocumab)
and the FOURIER Phase 3 trials.
Alirocumab
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular
Outcomes After an Acute Coronary Syndrome During
Treatment With Alirocumab) trial, with a median follow-up
of 2.8 years, enrolled patients with an acute coronary syn-
drome, already on intensive or maximum-tolerated statin
therapy. In order to achieve andmaintain an LDL cholester-
olaemia between 25 and 50mg/dL, two different doses of
alirocumab were used, i.e. 75 and 150mg. LDL-C fell by
53mg/dL which corresponds to a 55% decrement if com-
pared to placebo. The Kaplan–Meier rates for the primary
endpoint at 4 years showed that alirocumab taken every
other week led to a 15% reduction [hazard ratio (HR) 0.85;
95% CI: 0.78–0.93] in the MACEs, namely the composite of
coronary heart disease death, non-fatal myocardial infarc-
tion (MI), fatal or non-fatal ischaemic stroke, or unstable
angina requiring hospitalization. Specifically, the HRs were
0.92 (0.76, 1.11) for coronary heart disease death
(P¼ 0.38), 0.86 (0.77–0.96) for non-fatal MI (P¼ 0.006),
0.73 (0.57–0.93) for ischaemic stroke (P¼ 0.01), and 0.61
(0.41–0.92) for unstable angina.16 Interestingly, patients
given alirocumab experienced fewer non-fatal CV events
andwere less likely to die from a non-CVevent, being these
two findings statistically associated: HR 2.35 (95% CI:
1.98–2.73).17 Pre-specified subgroup analyses for the pri-
mary endpoint showed that the benefit was driven by the
effect seen in 5629 patients with baseline LDL-C
>100mg/dL. No significant differences between groups
were found for the secondary endpoints of death from
coronary heart disease and from CV causes. No statistical
differences were seen in the incidence of adverse events,
but local injection-site reactions (3.8% with alirocumab
vs. 2.1% in the placebo).16
Evolocumab
The efficacy of evolocumab in preventing MACEs, namely
the composite of CV death, MI, stroke, was tested in ath-
erosclerotic cardiovascular disease patients (ASCVD).
From February 2013 to June 2015, a total of 27 564
patients were randomly assigned to receive either evolo-
cumab (13 784) or placebo (13 780), 24% of whom were
women. After 48weeks, the primary endpoint occurred
in 9.8% of patients at evolocumab and in 11.3% of those
at placebo; the HR was 0.85 (95% CI 0.79–0.92), an effect
primarily ascribable to MI (27%), stroke (21%), and
coronary revascularization (22%) reductions. A step-
wise risk reduction was found: 12% during the first year
and 19% beyond the first year. Secondary endpoints,
namely the composite of CV death, MI, or stroke were
also reduced, HR 0.80 (95% CI 0.73–0.88). A 16% reduction
was seen during the first year reaching a 25% beyond the
first year. LDL cholesterolaemia whose basal levels were
92mg/dL dropped by 59% vs. placebo, i.e. 56mg/dL.
Interestingly, 87% of patients on evolocumab reached an
LDL cholesterolaemia 70mg/dL, 67% reached levels
40mg, and 42% levels25mg/dL.
Eleven thousand and thirty-one patients had diabetes vs.
16 533 who did not, evolocumab reduced primary endpoint
by a 17% vs. 13%, respectively. Same efficacy was seen for
the secondary key points with a percentage reduction of
18% and 22%, respectively. Evolocumab did not raise the
risk of new-onset diabetes in non-diabetics at baseline (HR:
1.05; 95% CI: 0.94–1.17) with no changes in the levels of
glycated haemoglobin and fasting plasma glucose.18
In an effort to comply with a cost-efficient medicine, a
post hoc analysis of FOURIER tested the hypothesis whether
or not the timing from the most recent MI, the number of
prior MIs, and the presence of residual multivessels CAD
could identify the most suitable subgroup benefitting the
most from the therapy. Among a total of 22351 patients,
representing 81% of the overall FOURIER trial, evolocumab
lowers both primary and secondary endpoints by 11% and
18%, respectively. When patients were stratified for timing
of qualifying MI (<2 years), number of prior Mis (2), and
residual multivessel coronary diseases (presence) the rela-
tive risk reduction was 20%, 18%, and 21% in the high-risk
subgroup vs. 5%, 8%, and 7% in those at lower risk, i.e. qual-
ifying MI >2 years, one prior MI with no multivessel coro-
nary diseases.19
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A further sub-analysis was the stratification of the
FOURIER trials in peripheral artery disease (PAD) symptom-
atic patients vs those without. In patients with PAD, the ab-
solute risk reduction for the primary endpoint was 3.5%
(NNT ¼ 29), a change rate superior to the 1.6% (NNT ¼ 63)
found in patients without PAD. Consistent with these data,
evolocumab was superior vs. placebo in reducing major ad-
verse limb events by 42% (HR 0.58; 95% CI: 0.38–0.88). This
benefit followed a linear relationship with LDL-C reduc-
tion, at least for values<10mg/dL.20
Finally, when the role of the inflammatory component,
i.e. baseline high sensitivity C-reactive protein (hsCRP) lev-
els, was considered, higher levels of C-reactive protein
(CRP) were associated with a higher absolute risk reduction
possibly due to an increased baseline ASCVD risk.
Stratification according to baseline hsCRP, i.e.<1, 1–3, and
>3mg/dL, led to an absolute reduction of 1.6%, 1.8%, and
2.6% for the primary endpoint.21
Conclusions
PCSK9 pharmacological therapy represents a new and valid
approach for controlling hypercholesterolaemia with con-
firmed CVD protective effect. However, considering the ef-
fect of evolocumab on mmol/L reduction in LDL-C,
treatment with evolocumab, in the FOURIER trial, reduced
the risk of the primary outcome by 11.0% per mmol/L re-
duction in LDL-C.22 The magnitude of this effect appears to
be slightly <22% reduction in risk per mmol/L reduction in
LDL-C during treatment with a statin as reported by CTT
collaboration for primary outcome.23,24 These apparently
discrepant results have been attributed to a shorter follow-
up of FOURIER (2.2years) compared to trials conducted
with statins (3–4 years).25 However, it is still possible that
therapies anti PCSK9 produce an anti-atherosclerotic activ-
ity which is mainly based on the reduction of the LDL-C lev-
els, while statins may possess the so-called ‘pleiotropic
effects’ beyond their lipid-lowering properties. This hy-
pothesis is mainly based on the evidence that statins signif-
icantly reduced CRP levels, while evolocumab and
alirocumab did not. In addition, differences in terms of
lipid-lowering properties have been observed between sta-
tins and PCSK9 inhibitors. Inhibition of PCSK9 seems to
have weaker effects on very-low-density lipoprotein lipids
compared with statins for an equivalent lowering of LDL-C,
which potentially translate into smaller reductions in CVD
risk. Finally, while statin therapy is associated to muscle-
related side effects, i.e. myalgia and myopathy, as well as
increased risk of new onset of Type 2 diabetes, PCSK9 inhib-
itor therapy does not seem to be associated to these side
effects.26 Thus, in conclusion, both statins and PCSK9
inhibitors elicit an effective LDL-C lowering effect; how-
ever, significant differences can be observed between the
two pharmacological approaches. Further clinical experi-
ence will better define the final outcomes between the
two approaches.
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